Atypical teratoid/rhabdoid tumors: challenges and search for solutions.
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal central nervous system tumor commonly affecting children <3 years of age. It roughly constitutes 1%-2% of all pediatric central nervous system tumors. Recent data show that it is the most common malignant central nervous system tumor in children <6 months of age. Management of this aggressive tumor is associated with a myriad of diagnostic and therapeutic challenges. On the basis of radiology and histopathology alone, distinction of AT/RT from medulloblastoma or primitive neuroectodermal tumor is difficult, and hence this tumor has been commonly misdiagnosed as primitive neuroectodermal tumor for decades. Presence of a bulky heterogeneous solid-cystic mass with readily visible calcification and intratumor hemorrhage, occurring off-midline in children <3 years of age, should alert the radiologist toward the possibility of AT/RT. Presence of rhabdoid cells on histopathology and polyphenotypic immunopositivity for epithelial, mesenchymal, and neuroectodermal markers along with loss of expression ofSMARCB1/INI1orSMARCA4/BRG1help in establishing a diagnosis of AT/RT. The optimal management comprises maximal safe resection followed by radiation therapy and multiagent intensive systemic chemotherapy. Gross total excision is difficult to achieve in view of the large tumor size and location and young age at presentation. Leptomeningeal spread is noted in 15%-30% of patients, and hence craniospinal irradiation followed by boost to tumor bed is considered standard in children older than 3 years. However, in younger children, craniospinal irradiation may lead to long-term neurocognitive and neuroendocrine sequel, and hence focal radiation therapy may be a pragmatic approach. In this age group, high-dose chemotherapy with autologous stem cell rescue may also be considered to defer radiation therapy, but this approach is also associated with significant treatment-related morbidity and mortality. Novel small molecule inhibitors hold promise in preclinical studies and should be considered in patients with relapsed or refractory tumor.
Department of Radiotherapy & Oncology.
Ahitagni
A
Biswas
Department of Radiotherapy & Oncology.
Lakhan
L
Kashyap
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Aanchal
A
Kakkar
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Chitra
C
Sarkar
Department of Radiotherapy & Oncology.
Pramod Kumar
PK
Julka
atypical teratoid/rhabdoid tumor; intracranial; medulloblastoma; primitive neuroectodermal tumor
J Pediatr Hematol Oncol. 2009 Sep;31(9):651-63
19707161
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):114-20
23498870
Cancer. 1984 Nov 15;54(10):2137-46
6091860
Cancer Biol Ther. 2009 Mar;8(5):412-6
19305156
J Clin Oncol. 2004 Jul 15;22(14):2877-84
15254056
Pediatr Dev Pathol. 2015 Jan-Feb;18(1):49-58
25494491
Front Oncol. 2012 Sep 12;2:114
22988546
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1756-63
21601374
PLoS One. 2008 May 07;3(5):e2090
18509505
Cancer. 1983 Jul 15;52(2):290-6
6861072
J Neurooncol. 2015 Sep;124(2):175-83
26148473
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1143-52
25311260
J Neurooncol. 2013 Sep;114(2):173-9
23836190
AJNR Am J Neuroradiol. 2015 Aug;36(8):1572-8
26138138
Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10 ):729-737
26469332
Pediatr Radiol. 2013 Aug;43(8):1001-8
23467756
Neuropathology. 2016 Feb;36(1):17-26
26207291
Cancer. 2012 Aug 1;118(15):3812-21
22180295
Neuro Oncol. 2016 Jun;18(6):764-78
26755072
Childs Nerv Syst. 2009 Jul;25(7):787-93
19082611
Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
21796761
Pediatr Blood Cancer. 2008 Aug;51(2):235-40
18381756
J Clin Oncol. 2009 Jan 20;27(3):385-9
19064966
Pediatr Hematol Oncol. 2003 Jun;20(4):327-32
12746165
Eur J Cancer. 2012 Feb;48(3):353-9
22023887
Phys Med Biol. 2012 Mar 7;57(5):1147-58
22330090
Cancer. 2012 Sep 1;118(17):4212-9
22213196
Cancer. 2010 Dec 15;116(24):5725-32
20737418
J Clin Oncol. 2005 Mar 1;23(7):1491-9
15735125
Neuroradiology. 2008 May;50(5):447-52
18345534
J Neurooncol. 2014 May;118(1):201-3
24574049
Acta Neurochir (Wien). 2015 Apr;157(4):589-96
25646852
Surg Neurol Int. 2014 May 23;5:75
24949218
J Neurosurg. 1996 Jul;85(1):56-65
8683283
Brain Tumor Res Treat. 2014 Oct;2(2):108-13
25408935
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
J Neurooncol. 2007 Jan;81(1):97-111
16855864
Acta Radiol. 2005 Feb;46(1):89-96
15841745
Childs Nerv Syst. 2001 Sep;17(9):503-11
11585322
J Neurooncol. 2012 Mar;107(1):111-9
21971736
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43
16406394
Cancer. 1978 May;41(5):1937-48
206343
J Clin Oncol. 2005 Oct 20;23(30):7621-31
16234523
Am J Surg Pathol. 2011 Jun;35(6):933-5
21566516
Childs Nerv Syst. 2015 Aug;31(8):1305-11
25953096
Pediatr Radiol. 2013 Mar;43(3):347-54
23143401
Brain Tumor Pathol. 2011 Feb;28(1):71-6
21181449
Cancer Med. 2014 Feb;3(1):91-100
24402832
Mol Cancer Res. 2014 Nov;12 (11):1574-85
25009291
J Neurooncol. 2013 Nov;115(2):209-15
23921420
J Neuropathol Exp Neurol. 2009 Dec;68(12 ):1249-55
19915490
J Clin Neurosci. 2001 Jan;8(1):1-3
11148073
Cancer Cell. 2016 Mar 14;29(3):379-93
26923874
Pediatr Neurosurg. 2002 Aug;37(2):64-70
12145514
Acta Neuropathol. 2000 May;99(5):482-8
10805090
Cancer. 2005 Nov 15;104(10):2156-67
16220552
Childs Nerv Syst. 2009 Nov;25(11):1495-500
19484251
J Clin Oncol. 1995 Mar;13(3):610-30
7884423
Cancer Cell Int. 2011 Dec 29;11(1):44
22206574
J Clin Oncol. 2004 Feb 15;22(4):706-13
14966095
Pediatr Blood Cancer. 2014 Jan;61(1):95-101
23934933
Acta Neuropathol. 2014 Sep;128(3):453-6
25060813
Neuro Oncol. 2014 Oct;16(10):1392-9
24847086
Acta Oncol. 2014 Apr;53(4):471-80
24564687
Oncotarget. 2015 Feb 20;6(5):3165-77
25638158
Am J Surg Pathol. 1998 Sep;22(9):1083-92
9737241
Childs Nerv Syst. 2009 May;25(5):535-41
19107490
Med Pediatr Oncol. 1992;20(3):258
1637409
Childs Nerv Syst. 2015 Oct;31(10):1717-28
26351225